Immunovant (IMVT)
(Real Time Quote from BATS)
$15.02 USD
-0.38 (-2.47%)
Updated Sep 19, 2025 11:00 AM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IMVT 15.02 -0.38(-2.47%)
Will IMVT be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for IMVT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IMVT
Immunovant (IMVT) Up 7.8% Since Last Earnings Report: Can It Continue?
IMVT Stock Up 11% on Upbeat Batoclimab Hyperthyroidism Study Results
IMVT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Immunovant's Q1 Loss Narrower Than Expected, Pipeline in Focus
All You Need to Know About Immunovant (IMVT) Rating Upgrade to Buy
Wall Street Analysts See a 137.68% Upside in Immunovant (IMVT): Can the Stock Really Move This High?
Other News for IMVT
NR7 appears for IMVT after 1.92% move
Is IMVT building bearish momentum? 20 Day Moving Average Resistance shows up after declining 1.18%
IMVT forms 20 Day Moving Average Resistance on September 16
Is IMVT primed for downward momentum? Fell Below 20 Day Moving Average shows up after sinking 3.9%
Tracking Baker Brothers Portfolio - Q2 2025 Update